How'd you fix Green Thumb Industries' revenue issues in 2026?

Inside a Typical MSO Margin Squeeze

Picture a multi-state cannabis operator that looks financially healthy on the surface: revenue is flat-to-growing, retail store count is expanding, and the brand is recognizable in half a dozen states. Underneath, gross margin has been sliding for six straight quarters. This is the exact pattern that shows up across the multi-state operator (MSO) category, and it is the pattern Green Thumb Industries had to confront going into 2026.

The mechanics are specific to cannabis but familiar to any RevOps practitioner who has worked a commoditizing market. Federal Section 280E disallows the deduction of ordinary business expenses against cannabis revenue — only cost of goods sold is deductible — which means a plant-touching company's effective tax rate runs far above what a normal C-corp in an adjacent industry pays. That single structural fact changes every other revenue decision downstream: a dollar of SG&A that would be tax-advantaged in most industries is not tax-advantaged here, so waste is punished harder, and margin recovery has to come from operations rather than accounting.

Layer onto that a retail landscape where store counts in mature markets like New Jersey and New York roughly doubled or tripled in a few years, and per-unit flower pricing fell sharply as new licenses came online. A company selling into that market sees the exact symptom GTI reported: revenue that holds steady while gross margin erodes, because average selling price is dropping faster than volume is rising. That is the scenario every fix has to be built against — not a demand problem, a unit-economics problem.

The other half of the scenario is competitive structure. In wholesale-heavy states like Illinois and Pennsylvania, an operator that grows more product than its own retail footprint can sell has to move the surplus through third-party distribution, often at compressed margins relative to what the same product would earn sold through owned stores or owned brands. When a competitor with a larger distribution network or lower cost basis controls a large share of that third-party channel, the grower is effectively a price-taker on a meaningful share of its harvest. That is the setup a revenue fix has to solve for: too much volume moving at wholesale-floor pricing, not enough moving at brand-controlled, DTC-adjacent pricing.

How the Margin-Recovery Playbook Works

The mechanism that turns a revenue-but-not-profit company around is a sequencing exercise: fix the controllable margin levers first, because they compound, and treat any external tailwind (like federal rescheduling) as upside rather than the plan itself. In practice this runs as a five-stage loop that repeats quarterly rather than a one-time project.

Stage one is SKU rationalization. Any operator running well over a thousand active SKUs across multiple states is almost certainly carrying a meaningful tail of items that lose money once fulfillment, shrink, and shelf-space opportunity cost are included. Pulling unit economics from point-of-sale and category-tracking data (the kind of retail panel data firms like BDSA and Headset provide across the cannabis industry) and cutting the bottom-performing 10-15% of SKUs is the fastest, lowest-risk margin action available, because it requires no new investment — only discipline to stop carrying dead weight.

Stage two is channel mix: shifting cultivation output away from low-margin third-party wholesale toward owned retail and owned-brand direct sales wherever the operator already has the store footprint or distribution partnerships to support it. Stage three is pricing discipline in saturated markets — explicitly refusing to chase the lowest competitor price on commodity flower, and instead defending price on differentiated, branded SKUs where the company controls positioning. Stage four is SG&A restructuring: consolidating redundant state-by-state back-office functions into regional or centralized hubs. Stage five is measurement — tying every one of the first four levers to a gross-margin-dollar target per store or per state, not a revenue target, so the incentive structure inside the RevOps and sales organization actually rewards the behavior the turnaround needs.

The important design choice in this loop is that it never depends on an external event. Federal rescheduling, if it happens, removes the 280E drag and adds meaningful EBITDA overnight — but a credible turnaround plan cannot be built on the assumption that Washington acts on a particular timeline. That is why the loop above treats SKU discipline, channel mix, pricing, and SG&A as the whole plan, with policy change bucketed separately as bonus upside.

The Numbers Behind the Turnaround

Cannabis MSOs of Green Thumb Industries' scale — roughly $1 billion in annual revenue, operating in a mix of limited-license and competitive-license states — typically report gross margins in the 45-55% range and adjusted EBITDA margins in the high teens to high twenties, with the spread between those two numbers driven heavily by SG&A ratio and by how much of revenue is retail (higher margin) versus wholesale (lower margin). An operator with EBITDA margin toward the low end of that band, closer to 18%, and a peer with a materially tighter cost structure running closer to 27-28%, illustrates exactly how much margin is sitting in operational discipline rather than in the top line.

Wholesale margins in competitive-license markets like Illinois and Pennsylvania commonly run in the high-30s to low-40s percent range, versus mid-40s to mid-50s percent for retail-captured or owned-brand sales in the same states — a spread wide enough that shifting even a modest share of volume, on the order of 15-20 percentage points, from wholesale to owned channels can move total company gross margin by several points. SG&A as a percentage of revenue is the other lever worth benchmarking: MSOs with disciplined back offices tend to land in the 6% range, while operators still running largely decentralized, state-by-state administrative functions can sit 1.5-2 points higher — a gap that on $1 billion of revenue is worth well into eight figures of annual overhead.

On pricing, mature East Coast recreational markets have seen average flower pricing compress from the mid-teens dollars per gram at early adult-use launch down toward single digits within a few years of new-license issuance, a roughly 40-50% price decline that no volume growth fully offsets. That is the core reason a revenue number can look stable or even grow while gross profit shrinks — the unit economics moved against the company faster than unit volume moved in its favor.

On the tax side, 280E's effect is large enough that it is worth quantifying directly: a plant-touching operator generally cannot deduct SG&A, marketing, or most non-COGS operating expenses for federal tax purposes, which commonly pushes effective federal tax rates into the 40-70% range on pre-tax income, versus the low-to-mid-20s percent an ordinary company in an adjacent consumer-products category would pay. If federal rescheduling moves cannabis to a lower drug schedule and removes the COGS-only deduction limitation, the swing in after-tax cash flow for a company GTI's size would plausibly be in the tens of millions of dollars annually — which is why credible turnaround plans model it as a separate, probability-weighted scenario rather than baking it into the base case.

Trade-offs and Alternative Paths

None of these levers is free, and a RevOps team running this playbook has to be explicit about what each one costs. Holding price discipline instead of matching a competitor's discount means accepting some volume loss — typically single-digit to low-double-digit percentage declines in unit sales in the segment where the price floor is enforced — in exchange for a larger improvement in margin dollars. That trade only pays off if the sales organization is actually measured and paid on margin dollars rather than units or revenue; if the incentive structure still rewards volume, front-line teams will quietly discount anyway and the policy will fail in practice even though it looks sound on paper.

Shifting cultivation output from wholesale to owned retail and DTC-style brand sales has a longer payback period than SKU cuts, because it requires either expanding owned retail footprint (capital-intensive, subject to state license caps) or building brand demand at the consumer level (marketing-intensive, slower to show up in the numbers). The alternative — staying wholesale-heavy — is lower-risk in the short term but caps the margin ceiling permanently, since wholesale pricing is set by the most aggressive competitor in the market, not by the seller.

An entirely different alternative path, one worth naming honestly, is portfolio pruning at the market level rather than the SKU level: exiting the weakest one or two state markets outright rather than trying to fix unit economics inside them. This is faster to execute and frees capital immediately, but it is also the most reversible-looking decision that is actually hardest to reverse — cannabis licenses are scarce and re-entering an exited state later is often impossible. That is the core trade-off of market exit versus market fix: speed and capital relief now, against permanently forfeiting optionality in a market that could still recover.

Cutting SG&A carries its own trade-off worth flagging separately: cannabis is one of the most heavily regulated consumer categories in the country, and state-level compliance, security, and track-and-trace reporting functions are not discretionary overhead — they are licensing requirements. A centralization push that treats every state team as fungible risks cutting into the compliance capacity that keeps the company licensed to operate at all. The right target for consolidation is duplicated corporate functions (finance, HR, procurement, IT), not the regulatory-facing staff embedded in each state.

Pitfalls That Derail the Fix

The single most common failure mode in a margin-recovery plan like this is sequencing it backwards — cutting SG&A first, before fixing channel mix and pricing, because headcount reduction is the fastest lever to pull and the one that shows up in the next quarter's numbers. Done first, without the revenue-quality fixes underneath it, it produces a company that is smaller and still structurally unprofitable, because the underlying wholesale-price-war and SKU-tail problems are untouched. The playbook works only when SG&A discipline is the last lever pulled, once the top of the funnel is already healthier.

A second pitfall is treating federal rescheduling as a plan rather than a scenario. Multiple MSOs have built budgets around an assumed rescheduling timeline that then slipped by a year or more, and companies that had not built a credible standalone operating plan were left with a revenue story but no margin story when the policy tailwind failed to arrive on schedule. Any RevOps-built turnaround plan should be stress-tested against a "rescheduling never happens" scenario before it is presented as credible.

A third pitfall is cutting SKUs or discounting programs using stale or incomplete data. Category-tracking panels like BDSA and Headset cover a large share of licensed dispensary sales but not all of it, and a SKU that looks like a loser in aggregate state data can still be a top performer in a specific high-volume store. Applying a blunt, state-level SKU cut without a store-level override step risks removing products that are actually profitable in the locations that matter most, which erodes trust in the data-driven process and makes the next round of cuts harder to execute.

A fourth pitfall is under-investing in the incentive redesign that has to accompany a pricing-discipline push. If regional or store-level managers are still compensated primarily on revenue or unit volume, telling them to hold price is asking them to act against their own paycheck — and most will not, regardless of what corporate policy says. The compensation plan has to change in the same quarter the pricing policy changes, not two quarters later, or the policy is cosmetic.

Finally, a pitfall specific to companies the size of Green Thumb Industries is moving too slowly on consolidation because every state operation has its own legal entity, its own state-specific compliance requirements, and its own local relationships. That complexity is real, but it becomes an excuse for indefinite delay if there is no forcing function. The fix that works in practice sets a hard external deadline — a specific quarter — for every consolidation decision, rather than letting state-by-state negotiation drag the timeline out indefinitely.

Related questions

Why does 280E hurt cannabis companies more than a normal retailer?

Because federal tax law disallows deducting ordinary business expenses — only cost of goods sold — against cannabis revenue, pushing effective tax rates well above what a non-cannabis retailer pays on the same pre-tax income, and making overhead waste far more expensive to carry.

What's the difference between wholesale and retail margin in cannabis?

Wholesale margins in competitive markets often sit in the high-30s to low-40s percent range because the seller is a price-taker; retail and owned-brand sales typically run 10-15 points higher because the company controls both product and pricing to the end consumer.

How do MSOs use data like BDSA or Headset in a turnaround?

These retail-panel data providers track point-of-sale performance across licensed dispensaries, letting operators identify which SKUs, categories, and price points are actually profitable rather than relying on gut instinct or stale internal reporting.

Is exiting a state market ever the right revenue fix?

Sometimes — it delivers the fastest capital relief — but cannabis licenses are scarce and often non-reissuable, so exiting forfeits optionality permanently in a way that operational fixes inside the market do not.

FAQ

Did Green Thumb Industries have a revenue problem or a margin problem in 2026? Primarily a margin problem. Revenue held near $1 billion, but gross and EBITDA margins were compressed by 280E tax treatment, wholesale price competition, and overhead levels typical of a company still running largely decentralized state operations.

Why focus on SKU cuts before anything else? SKU rationalization is the lowest-risk, fastest-to-execute margin lever because it requires no new capital or headcount changes — just removing items that lose money once fulfillment and shrink are accounted for, based on unit-economics data.

Does federal cannabis rescheduling actually fix the revenue issue on its own? It would meaningfully improve after-tax cash flow by removing the 280E COGS-only deduction limit, but a credible plan cannot rely on a policy timeline that has already slipped before — operational fixes have to stand on their own.

Why does pricing discipline matter more in New Jersey and New York specifically? Both markets saw rapid store-count growth and steep per-gram price declines as new licenses came online, so an operator that keeps discounting to match every competitor locks in permanently lower margin in exactly the markets where it has the most volume.

How does RevOps fit into a plan like this? RevOps ties the operational levers — SKU mix, channel mix, pricing floors, SG&A structure — to the incentive systems that determine whether store and regional teams actually execute them, which is the step that most turnaround plans skip.

What's the biggest risk in cutting SG&A at a cannabis MSO? Cutting into state-level compliance, security, or track-and-trace staff, which are licensing requirements rather than discretionary overhead — the safer target is duplicated corporate functions like finance, HR, and procurement.

Sources

• https://www.sec.gov
• https://mjbizdaily.com
• https://www.cannabisbusinesstimes.com
• https://www.statista.com
• https://bdsa.com
• https://www.headset.io
• https://www.marijuanamoment.net
• https://gtigrows.com/investors

Related on PULSE

• Should I open or buy a Crisp & Green franchise in 2027?
• Which 2027 procurement mandates are extending sales cycles by 40% in regulated industries?
• Why are 2027's longest sales cycles concentrated in industries where buying committees still enforce manual compliance checks?
• What specific legal concerns are delaying the adoption of AI sales assistants in regulated industries?
• What specific RevOps compliance risks arise when using AI to score buying committee members in regulated industries like healthcare in 2027?